1. Docter R, Bos G, Visser TJ, Hennemann G. Thyrotropin binding inhibiting immunoglobulins in Graves’ disease before, during and after antithyroid therapy, and its relation to long-acting thyroid stimulator. Clin Endocrinol 12:143. 1980.
2. Hinds WE, Takas N, Rapoport B, Filette S, Clark OH. Thyroid-stimulating immunoglobulin bioassay using cultured human thyroid cells. J Clin Endocrinol Metab 51:1204. 1981.
3. Cho BY, Koh CS, Lee M. The clinical significance of TSH binding inhibiting immunoglobulin in autoimmune thyroid diseases. Korean J Intern Med 28:299. 1985.
4. Koh CS. The roles of the TSH receptor antibodies in autoimmune thyroid diseases. Korean J Nucl Med 20:85. 1986.
5. Roitt IM, Torrigiani G. Identification and estimation of undegraded thyroglobulin in human serum. Endocrinology 81:42. 1967.
6. Torrigiani G, Doniach D, Roitt IM. Serum thyroglobulin levels in healthy subjects and in patients with thyroid disease. J Clin Endocrinol Metab 29:305. 1969.
7. Schneider AB, Ikekubo K. Measurement of thyroglobulin in the circulation: clinical and technical considerations. Ann Lab Sci 9:230. 1979.
8. Bach JF, Carnaud C. Thymic factors. Prog Allergy 21:342. 1976.
9. Shenkman L, Bottone EJ. Antibodies to Yersinia enterocolitica in thyroid disease. Ann Intern Med 85:735. 1976.
10. Topliss D, How J, Lewis M, Row V, Volpe R. Evidence for cell-mediated immunity and specific suppressor T-lymphocyte dysfunction in Graves’ diseases and diabetes mellitus. J Clin Endocrinol Metab 57:700. 1983.
11. Tao TW, Gatenby PA, Leu SL, Pham H, Kriss JP. Helper and suppressor activities of lymphocyte subsets on antithyroglobulin production in vitro. J Clin Endocrinol Metab 61:520. 1985.
12. Stenszky V, Kozma L, Balazs CS, Rochlitz SZ, Bear JC, Farid NR. The genetics of Graves’ disease: HLA and disease susceptibility. J Clin Endocrinol Metab 61:735. 1985.
13. Cho BY, Rhee BD, Lee DS, Lee MS, Kim GY, Lee HK, Koh CS, Min HK, Lee M. HLA and Graves’ disease in Korean. Seoul J Med 28:19. 1987.
14. Hanafusa T, Pujol-Borrel R, Chivato L, Russel RCG, Doniach D, Botazzo GF. Aberrant expression of HLA-DR antigen on thyrocytes in Graves’ disease: relevance for autoimmunity. Lancet 2:1111. 1983.
15. Jansson R, Karlsson A, Forsum U. Intrathyroidal HLA-DR expression and T-lymphocyte phenotypes in Graves’ thyrotoxicosis, Hashimoto’s thyroiditis and nodular colloid goiter. Clin Exp Immunol 58:264. 1984.
16. Pujol-Borrell R, Hanafusa T, Chivato L, Bottazzo GF. Lectin-induced expression of DR antigen on human cultured follicular thyroid cells. Nature 304:71. 1983.
17. Bottazzo GF, Pujol-Borrel R, Hanafusa T. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet 2:1115. 1983.
19. Kaufman JF, Auffray C, Korman AJ, Shackelford A, Strominger J. The class II molecules of the human and murine major histocompatibility complex. Cell 36:1. 1984.
20. Weir DM. Handbook of experimental immunology. 2:Cellular Immunology. 4th ed. 721. Oxford: Blackwell Scientific Publication, 1986.
21. Bottazzo GF, Dean BM, McNally JM, MacKay EH, Swift PGF, Gamble DR. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med 313:353. 1985.
22. Ballardini G, Mirakian R, Bianchi FB, Pisi E, Doniach D, Bottazzo GF. Aberrant expression of HLA-DR antigens on bile duct epithelium in primary biliary cirrhosis: relevance to pathogenesis. Lancet 2:1009. 1984.
23. Cha CY, Hwang ES, Cho MJ, Park MH, Ahn HS, Kim NK, Chang WH, Lee M. Production and characterization of lymphocytic hybridomas secreting monoclonal antibodies reactive with the cell surface antigens of acute lymphoblastic leukemia. J Korean Med Assoc 27:253. 1984.
24. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KAF, Stein H, Mason DY. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (AP-AAP complexes). J Histochem Cytochem 32:219. 1984.
25. Lansdorp PM, Kwast THVD, Boer MD, Zeijlemaker . Stepwise amplified immunoperoxidase (PAP) Staining:cellullar morphology in relation to membrane markers. J Histochem Cytochem 32:172. 1984.
26. Steinman RM. Dendritic cells. Transplantation 31:151. 1981.
27. Poulter LW. Antigen presenting cells in situ:their identification and involvement in immunopathology. Clin Exp Immunol 53:513. 1983.
28. Fuggle SV, Errasti P, Daar AS, Fabre JW, Ting A, Morris PJ. Localization of major histocompatibility complex (HLA-ABC and DR) antigens in 46 kidneys. Transplantation 35:385. 1983.
29. Rose NR, Friedman H, Fahey JL. Manual of clinical laboratory immunology. 3rd ed. 924. Washington DC: American Society for Microbiology, 1986.
30. Weetman AP, Volkman DJ, Burman KD, Gerrard TL, Fauci AS. The in vitro regulation of human thyrocytes HLA-DR antigen expression. J Clin Endocrinol Metab 61:817. 1985.
31. Iwatani Y, Gersterin HC, Iitaka M, Row VV, Volpe R. Thyrocyte HLA-DR expression and interferon-gamma production in autoimmune thyroid disease. J Clin Endocrinol Metab 63:695. 1986.
32. Pujol-Borrell R, Todd I, Doshi M, Bottazzo GF, Sutton R, Gray D, Adolf GR, Feldmann M. HLA class II induction in human islet cells by interferon-gamma plus tumor necrosis factor or lymphotoxin. Nature 329:304. 1987.
33. Londei M, Lamb JR, Bottazzo GF, Feldmann M. Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells. Nature 312:639. 1984.
36. Reinherz EL, Morimoto C, Penta AC, Schlossman SF. Subpopulation of the T4 + inducer T-cell subset in man: evidence for an amplifier population preferentially expressing Ia antigen upon activation. J Immunol 126:67. 1981.